The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices
Abstract
Purpose: This retrospective study was undertaken to assess practice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incidence and predictive factors of reduced relative dose-intensity (RDI). Patients and Methods: A nationwide survey of 1,243 community oncology practices was conducted, with data extracted from records of 20,799 ESBC patients treated with adjuvant chemotherapy. Assessments included demographic and clinical characteristics, chemotherapy dose modifications, incidence of febrile neutropenia, and patterns of use of colony-stimulating factor (CSF). Dose-intensity was compared with published reference standard regimens. Results: Dose reductions ≥15% occurred in 36.5% of patients, and there were treatment delays ≥7 days in 24.9% of patients, resulting in 55.5% of patients receiving RDI less than 85%. Nearly two thirds of patients received RDI less than 85% when adjusted for differences in regimen dose-intensity. Multivariate analysis identified several independent predictors for reduced RDI, including increased age; chemotherapy with cyclophosphamide, methotrexate, and fluorouracil, or cyclophosphamide, doxorubicin, and fluorouracil; a 28-day schedule; body-surface area greater than 2 m 2 ; and no primary CSF prophylaxis. CSF was often initiated late in the chemotherapy cycle. Conclusion: Patients with ESBC are at substantial risk for reduced RDI when treated with adjuvant chemotherapy. Patients at greatest risk include older patients, overweight patients, and those receiving three-drug combinations or 28-day schedules. Predictive models based on such risk factors should enable the selective application of supportive measures in an effort to deliver full dose-intensity chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., Kris, M., Grous, J., Picozzi, V., Rausch, G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250305 · Cited by 1,390
Self-citationCombination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C., De Lena, M., Tancini, G., Bajetta, E., Musumeci, R., et al. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602192940801 · Cited by 1,329
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,049
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Self-citationFisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620
Cited by
Chemotherapy‐induced neutropenia: Risks, consequences, and new directions for its management
Crawford, J., Dale, D. C., & Lyman, G. H. (2004) · Cancer · doi:10.1002/cncr.11882 · Cited by 882
Self-citationKuderer, N. M., Dale, D. C., Crawford, J., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8823 · Cited by 720
Self-citationAdjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Muss, H. B., Berry, D. A., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B., Partridge, A. H., Dressler, L. G., Cohen, H. J., Becker, H. P., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810266 · Cited by 554
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Self-citationGriggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T. M., Runowicz, C. D., Rosner, G. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9436 · Cited by 485
Self-citationAdjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer
Muss, H. B. (2005) · JAMA · doi:10.1001/jama.293.9.1073 · Cited by 418
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Lyman, G. H. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0009 · Cited by 383
Self-citationEORTC elderly task force position paper: Approach to the older cancer patient
Pallis, A. G., Fortpied, C., Wedding, U., Van Nes, M. C., Penninckx, B., Ring, A., Lacombe, D., Monfardini, S., Scalliet, P., & Wildiers, H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.022 · Cited by 340
Risk Models for Predicting Chemotherapy-Induced Neutropenia
Lyman, G. H., Lyman, C. H., Agboola, O., & Anc Study Group (2005) · The Oncologist · doi:10.1634/theoncologist.10-6-427 · Cited by 336
Self-citationUse and outcomes of adjuvant chemotherapy in older women with breast cancer
Giordano, S. H., Duan, Z., Kuo, Y.-F., Hortobagyi, G. N., & Goodwin, J. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3028 · Cited by 318
Lyman, G. H., Dale, D. C., Friedberg, J., Crawford, J., & Fisher, R. I. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.213 · Cited by 315
Self-citationRacial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer
Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., & Neugut, A. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.633 · Cited by 308
Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A.-T., & Vlastos, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4208 · Cited by 306
Bland, K. A., Zadravec, K., Landry, T., Weller, S., Meyers, L., & Campbell, K. L. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.005 · Cited by 109
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Han, Y., Yu, Z., Wen, S., Zhang, B., Cao, X., & Wang, X. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1799-1 · Cited by 69
“However, chemotherapy dose reductions and dose delays, as a result of chemotherapy-induced neutropenia, can lead to reduce patient survival [37–39].”
BackgroundNeugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L., Leoce, N., Nathanson, S. D., Ambrosone, C. B., Bovbjerg, D. H., Mandelblatt, J. S., Magai, C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2066-9 · Cited by 63
Metadata
- Authors
- Lyman, G. H., Dale, D. C., & Crawford, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-12-15
- Volume
- 21
- Issue
- 24
- Pages
- 4524-4531
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2055543087
- Cited by
- 464
- References
- 22
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.